Table 2.
Treatment Outcome, Best Response by RECIST v1.1
| All | Aged < 65 years | Aged ≥ 65 years | P value | |
|---|---|---|---|---|
| N = 540 | N = 448 | N = 92 | ||
| Best response, n (%) | 0.003 | |||
| PR | 83 (15.4) | 72 (16.1) | 11 (12.0) | |
| SD | 301 (55.7) | 237 (52.9) | 64 (69.6) | |
| PD | 155 (28.7) | 139 (31.0) | 16 (17.4) | |
| NE | 1 (0.19) | 0 (0.00) | 1 (1.09) | |
| ORR, n (%) | 83 (15.4) | 72 (16.1) | 11 (12.1) | 0.423 |
| DCR, n (%) | 384 (71.2) | 309 (69.0) | 75 (82.4) | 0.014 |
| PFS, days median (95% CI) | 193 (176–218) | 182 (168–204) | 258 (210–337) | |
| OS, days median (95% CI) | 569 (510–715) | 569 (578–799) | 482 (415–NA) |
Categorical values are shown as n (%)
RECIST response evaluation criteria in solid tumors, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate, PFS progression-free survival, OS overall survival, n number, CI confidence interval